Daniela Galimberti

List of Publications by Year in Descending Order

297 papers	21,120 citations	62 h-index	139 g-index
305 ext. papers	24,643 ext. citations	6.1 avg, IF	5.81 L-index

#	Paper	IF	Citations
297	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. *Annals of Neurology*, **2021**,	9.4	2
296	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**,	5.5	3
295	The distinct roles of monoamines in multiple sclerosis: A bridge between the immune and nervous systems?. *Brain, Behavior, and Immunity*, **2021**, 94, 381-391	16.6	4
294	Fluid biomarkers in frontotemporal dementia: past, present and future. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 204-215	5.5	19
293	Disease-related cortical thinning in presymptomatic granulin mutation carriers. *NeuroImage: Clinical* , **2021**, 29, 102540	5.3	2
292	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. *Neurobiology of Aging*, **2020**, 87, 139.e1-139.e7	5.6	13
291	Cerebrospinal fluid glutamate changes in functional movement disorders. *Npj Parkinsonjs Disease*, **2020**, 6, 37	9.7	4
290	C9ORF72 hexanucleotide repeat expansion frequency in patients with Paget's disease of bone. *Neurobiology of Aging*, **2020**, 85, 154.e1-154.e3	5.6	2
289	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. *Annals of Neurology*, **2020**, 88, 113-122	9.4	11
288	Inflammatory expression profile in peripheral blood mononuclear cells from patients with Nasu-Hakola Disease. *Cytokine*, **2019**, 116, 115-119	4	4
287	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. *NeuroImage*, **2019**, 189, 645-654	7.9	18
286	ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is impaired in Alzheimer's disease. *Journal of Lipid Research*, **2019**, 60, 1449-1456	6.3	25
285	Lag-time in Alzheimer's disease patients: a potential plasmatic oxidative stress marker associated with ApoE4 isoform. *Immunity and Ageing*, **2019**, 16, 7	9.7	11
284	Untangling Extracellular Proteasome-Osteopontin Circuit Dynamics in Multiple Sclerosis. *Cells*, **2019**, 8,	7.9	8
283	Exploring the role of BDNF DNA methylation and hydroxymethylation in patients with obsessive compulsive disorder. *Journal of Psychiatric Research*, **2019**, 114, 17-23	5.2	14
282	The Neuroanatomy of Somatoform Disorders: A Magnetic Resonance Imaging Study. *Psychosomatics*, **2019**, 60, 278-288	2.6	6
281	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. *NeuroImage*, **2019**, 188, 282-290	7.9	10

280	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. *Neurobiology of Aging*, **2019**, 77, 169-177	5.6	24
279	Structural and metabolic cerebral alterations between elderly bipolar disorder and behavioural variant frontotemporal dementia: A combined MRI-PET study. *Australian and New Zealand Journal of Psychiatry*, **2019**, 53, 413-423	2.6	11
278	The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients. *Multiple Sclerosis Journal*, **2019**, 25, 31-38	5	25
277	Microtubule defects in mesenchymal stromal cells distinguish patients with Progressive Supranuclear Palsy. *Journal of Cellular and Molecular Medicine*, **2018**, 22, 2670-2679	5.6	8
276	Profiling of Specific Gene Expression Pathways in Peripheral Cells from Prodromal Alzheimer's Disease Patients. *Journal of Alzheimerjs Disease*, **2018**, 61, 1289-1294	4.3	1
275	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 548-558	24.1	60
274	Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer's Disease and Frontotemporal Dementia. *Journal of Alzheimerjs Disease*, **2018**, 62, 913-932	4.3	31
273	Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI). *Journal of Magnetic Resonance Imaging*, **2018**, 47, 131-140	5.6	32
272	CSF □amyloid and white matter damage: a new perspective on Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 352-357	5.5	30
271	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. *Neurobiology of Aging*, **2018**, 62, 191-196	5.6	104
270	Regulation of gene transcription in bipolar disorders: Role of DNA methylation in the relationship between prodynorphin and brain derived neurotrophic factor. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2018**, 82, 314-321	5.5	17
269	PICALM Gene Methylation in Blood of Alzheimer's Disease Patients Is Associated with Cognitive Decline. *Journal of Alzheimerjs Disease*, **2018**, 65, 283-292	4.3	11
268	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. *Alzheimerjs Research and Therapy*, **2018**, 10, 46	9	24
267	Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort. *Journal of Alzheimerjs Disease*, **2018**, 65, 147-163	4.3	17
266	Comparison of □-microglobulin serum level between Alzheimer's patients, cognitive healthy and mild cognitive impaired individuals. *Biomarkers*, **2018**, 23, 603-608	2.6	8
265	Progranulin as a therapeutic target for dementia. *Expert Opinion on Therapeutic Targets*, **2018**, 22, 579-585	3.4	11
264	Word and Picture Version of the Free and Cued Selective Reminding Test (FCSRT): Is There Any Difference?. *Journal of Alzheimerjs Disease*, **2018**, 61, 47-52	4.3	4
263	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. *Neurobiology of Aging*, **2018**, 62, 245.e9-245.e12	5.6	30

262	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. *Nature Communications*, **2018**, 9, 4273	17.4	125
261	CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia. *Neurobiology of Aging*, **2018**, 72, 171-176	5.6	15
260	Epigenetic regulatory modifications in genetic and sporadic frontotemporal dementia. *Expert Review of Neurotherapeutics*, **2018**, 18, 469-475	4.3	4
259	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. *Journal of Alzheimerjs Disease*, **2017**, 56, 543-555	4.3	7
258	Effects of Multiple Genetic Loci on Age at Onset in Frontotemporal Dementia. *Journal of Alzheimerjs Disease*, **2017**, 56, 1271-1278	4.3	3
257	Recognition of viral and self-antigens by T1 and T1/T17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 797-808	11.5	46
256	Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. *Scientific Reports*, **2017**, 7, 43718	4.9	29
255	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. *Brain*, **2017**, 140, 1784-1791	11.2	31
254	The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance?. *Trends in Immunology*, **2017**, 38, 498-512	14.4	43
253	White matter hyperintensities are seen only in mutation carriers in the GENFI cohort. *NeuroImage: Clinical*, **2017**, 15, 171-180	5.3	43
252	Consensus guidelines for lumbar puncture in patients with neurological diseases. *Alzheimerjs and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 8, 111-126	5.2	128
251	Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review. *Journal of Geriatric Psychiatry and Neurology*, **2017**, 30, 162-169	3.8	15
250	Self-Awareness for Memory Impairment in Amnestic Mild Cognitive Impairment: A Longitudinal Study. *American Journal of Alzheimerjs Disease and Other Dementias*, **2017**, 32, 401-407	2.5	4
249	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature Genetics*, **2017**, 49, 1373-1384	36.3	508
248	CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis. *Multiple Sclerosis Journal*, **2017**, 23, 1085-1091	5	23
247	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. *Neurological Sciences*, **2017**, 38, 83-91	3.5	10
246	Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation. *Movement Disorders*, **2017**, 32, 476-478	7	6
245	Pioglitazone for the treatment of Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2017**, 26, 97-101	5.9	62

244	Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. *Journal of Alzheimerjs Disease*, **2017**, 55, 315-320	4.3	25
243	Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. *Journal of Alzheimerjs Disease*, **2017**, 55, 59-65	4.3	26
242	Old and new acetylcholinesterase inhibitors for Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2016**, 25, 1181-7	5.9	63
241	Non Fluent Variant of Primary Progressive Aphasia Due to the Novel GRN g.9543delA(IVS3-2delA) Mutation. *Journal of Alzheimerjs Disease*, **2016**, 54, 717-21	4.3	5
240	Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 1007-12	5	10
239	Iron in Frontotemporal Lobar Degeneration: A New Subcortical Pathological Pathway?. *Neurodegenerative Diseases*, **2016**, 16, 172-8	2.3	16
238	Gene promoter methylation and expression of Pin1 differ between patients with frontotemporal dementia and Alzheimer's disease. *Journal of the Neurological Sciences*, **2016**, 362, 283-6	3.2	16
237	Hemodynamic and Anatomic Variations Require an Adaptable Approach during Intra-Arterial Chemotherapy for Intraocular Retinoblastoma: Alternative Routes, Strategies, and Follow-Up. *American Journal of Neuroradiology*, **2016**, 37, 1289-95	4.4	29
236	Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. *Acta Neuropathologica*, **2016**, 131, 925-33	14.3	201
235	Weight Loss Predicts Progression of Mild Cognitive Impairment to Alzheimer's Disease. *PLoS ONE*, **2016**, 11, e0151710	3.7	46
234	A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status. *Journal of Visualized Experiments*, **2016**,	1.6	2
233	PRNP P39L Variant is a Rare Cause of Frontotemporal Dementia in Italian Population. *Journal of Alzheimerjs Disease*, **2016**, 50, 353-7	4.3	12
232	Plasma Screening for Progranulin Mutations in Patients with Progressive Supranuclear Palsy and Corticobasal Syndromes. *Journal of Alzheimerjs Disease*, **2016**, 53, 445-9	4.3	3
231	Reversible Mild Cognitive Impairment: The Role of Comorbidities at Baseline Evaluation. *Journal of Alzheimerjs Disease*, **2016**, 51, 57-67	4.3	26
230	CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients. *Journal of Alzheimerjs Disease*, **2016**, 52, 1203-8	4.3	12
229	Neuroimaging Correlates of Frontotemporal Dementia Associated with SQSTM1 Mutations. *Journal of Alzheimerjs Disease*, **2016**, 53, 303-13	4.3	8
228	Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis. *Journal of Neuroimmunology*, **2016**, 299, 81-83	3.5	27
227	Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2015**, 21, 1431-42	5	18

226	The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. *Acta Neuropathologica*, **2015**, 129, 715-27	14.3	101
225	Inflammatory molecules in Frontotemporal Dementia: cerebrospinal fluid signature of progranulin mutation carriers. *Brain, Behavior, and Immunity*, **2015**, 49, 182-7	16.6	34
224	Ball's concentric sclerosis: still to be considered as a variant of multiple sclerosis?. *Neurological Sciences*, **2015**, 36, 2277-80	3.5	5
223	Profiling of ubiquitination pathway genes in peripheral cells from patients with frontotemporal dementia due to C9ORF72 and GRN mutations. *International Journal of Molecular Sciences*, **2015**, 16, 1385-94	6.3	9
222	A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. *Neurobiology of Aging*, **2015**, 36, 2904.e13-26	5.6	34
221	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. *Brain*, **2015**, 138, 918-31	11.2	103
220	Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2015**, 16, 86-91	3.6	47
219	EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. *European Journal of Neurology*, **2015**, 22, 889-98	6	81
218	Psychiatric symptoms in frontotemporal dementia: epidemiology, phenotypes, and differential diagnosis. *Biological Psychiatry*, **2015**, 78, 684-92	7.9	52
217	Mutation analysis of CHCHD10 in different neurodegenerative diseases. *Brain*, **2015**, 138, e380	11.2	67
216	MRI helps depict clinically undetectable risk factors in advanced stage retinoblastomas. *Neuroradiology Journal*, **2015**, 28, 53-61	2	3
215	CHCHD10 mutations in Italian patients with sporadic amyotrophic lateral sclerosis. *Brain*, **2015**, 138, e372	11.2	49
214	Convergent genetic and expression data implicate immunity in Alzheimer's disease. *Alzheimerjs and Dementia*, **2015**, 11, 658-71	1.2	146
213	The novel GRN g.1159_1160delTG mutation is associated with behavioral variant frontotemporal dementia. *Journal of Alzheimerjs Disease*, **2015**, 44, 277-82	4.3	6
212	Binge eating and fast cognitive worsening in an early-onset bvFTD patient carrying C9ORF72 expansion. *Neurocase*, **2015**, 21, 543-7	0.8	1
211	Transmembrane protein 106B gene (TMEM106B) variability and influence on progranulin plasma levels in patients with Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2015**, 43, 757-61	4.3	2
210	SORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimer's Disease. *Journal of Alzheimerjs Disease*, **2015**, 46, 771-6	4.3	13
209	Frontotemporal Lobar Degeneration **2015**, 57-66		1

208	Idalopirdine as a treatment for Alzheimer's disease. *Expert Opinion on Investigational Drugs*, **2015**, 24, 981-7	5.9	13
207	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. *Molecular Neurodegeneration*, **2015**, 10, 64	19	87
206	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. *Lancet Neurology, The*, **2015**, 14, 253-62	24.1	328
205	Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy. *Neurological Sciences*, **2015**, 36, 751-7	3.5	8
204	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. *Multiple Sclerosis Journal*, **2015**, 21, 1013-24	5	181
203	TREM2 regulates microglial cell activation in response to demyelination in vivo. *Acta Neuropathologica*, **2015**, 129, 429-47	14.3	136
202	Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy. *PLoS ONE*, **2015**, 10, e0140639	3.7	4
201	Brain temperature in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 894-6	5	2
200	Innate immune system and inflammation in Alzheimer's disease: from pathogenesis to treatment. *NeuroImmunoModulation*, **2014**, 21, 79-87	2.5	66
199	Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis. *Neurological Sciences*, **2014**, 35, 789-91	3.5	6
198	Circulating miRNAs as potential biomarkers in Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2014**, 42, 1261-7	4.3	143
197	Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurology, The*, **2014**, 13, 686-99	24.1	207
196	Heterozygous TREM2 mutations in frontotemporal dementia. *Neurobiology of Aging*, **2014**, 35, 934.e7-10	5.6	107
195	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. *Neurology* , **2014**, 83, 1210-6	6.5	26
194	Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions. *Neurobiology of Aging*, **2014**, 35, 2658.e1-2658.e5	5.6	27
193	C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. *Neurobiology of Aging*, **2014**, 35, 1214.e7-1214.e10	5.6	44
192	C9ORF72 repeat expansion not detected in patients with multiple sclerosis. *Neurobiology of Aging*, **2014**, 35, 1213.e1-2	5.6	5
191	No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis. *Journal of Neuroimmunology*, **2014**, 271, 49-52	3.5	1

190	Epigenetic modulation of BDNF gene: differences in DNA methylation between unipolar and bipolar patients. *Journal of Affective Disorders*, **2014**, 166, 330-3	6.6	71
189	Phenotypic variability associated with the C9ORF72 hexanucleotide repeat expansion: a sporadic case of frontotemporal lobar degeneration with prodromal hyposmia and predominant semantic deficits. *Journal of Alzheimerjs Disease*, **2014**, 40, 849-55	4.3	5
188	Possible association between SNAP-25 single nucleotide polymorphisms and alterations of categorical fluency and functional MRI parameters in Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2014**, 42, 1015-28	4.3	26
187	Incomplete penetrance of the C9ORF72 hexanucleotide repeat expansions: frequency in a cohort of geriatric non-demented subjects. *Journal of Alzheimerjs Disease*, **2014**, 39, 19-22	4.3	26
186	Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy. *Immunotherapy*, **2014**, 6, 23-8	3.8	2
185	Hypermethylation of the CpG-island near the C9orf72 G□□repeat expansion in FTLD patients. *Human Molecular Genetics*, **2014**, 23, 5630-7	5.6	68
184	Physical activity reduces the risk of dementia in mild cognitive impairment subjects: a cohort study. *Journal of Alzheimerjs Disease*, **2014**, 39, 833-9	4.3	53
183	Genetic analysis of matrin 3 gene in French amyotrophic lateral sclerosis patients and frontotemporal lobar degeneration with amyotrophic lateral sclerosis patients. *Neurobiology of Aging*, **2014**, 35, 2882.e13-2882.e15	5.6	23
182	C9ORF72 hexanucleotide repeat expansion as a rare cause of bipolar disorder. *Bipolar Disorders*, **2014**, 16, 448-9	3.8	26
181	Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis. *Autoimmune Diseases*, **2014**, 2014, 739705	2.9	26
180	Is HCRTR2 a genetic risk factor for Alzheimer's disease?. *Dementia and Geriatric Cognitive Disorders*, **2014**, 38, 245-53	2.6	16
179	Progranulin gene variability influences the risk for bipolar I disorder, but not bipolar II disorder. *Bipolar Disorders*, **2014**, 16, 769-72	3.8	15
178	Clinical and MRI correlates of disease progression in a case of nonfluent/agrammatic variant of primary progressive aphasia due to progranulin (GRN) Cys157LysfsX97 mutation. *Journal of the Neurological Sciences*, **2014**, 342, 167-72	3.2	12
177	Evidence of pre-synaptic dopaminergic deficit in a patient with a novel progranulin mutation presenting with atypical parkinsonism. *Journal of Alzheimerjs Disease*, **2014**, 38, 747-52	4.3	12
176	Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. *PLoS ONE*, **2014**, 9, e94661	3.7	90
175	Frontotemporal Lobar Degeneration: Genetics and Clinical Phenotypes **2014**, 93-109		
174	Progress in Alzheimer's disease research in the last year. *Journal of Neurology*, **2013**, 260, 1936-41	5.5	10
173	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. *Nature Genetics*, **2013**, 45, 1353-60	36.3	934

172	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nature Genetics*, **2013**, 45, 1452-8	36.3	2714
171	Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. *Neurological Sciences*, **2013**, 34, 899-903	3.5	25
170	Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: late-onset psychotic clinical presentation. *Biological Psychiatry*, **2013**, 74, 384-91	7.9	94
169	Expression of the transcription factor Sp1 and its regulatory hsa-miR-29b in peripheral blood mononuclear cells from patients with Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2013**, 35, 487-94	4.3	52
168	Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. *Neurobiology of Aging*, **2013**, 34, 1517.e9-10	5.6	31
167	Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis. *International Journal of Molecular Sciences*, **2013**, 14, 4375-84	6.3	53
166	Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis. *European Journal of Immunology*, **2013**, 43, 2089-100	6.1	62
165	Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. *Neurobiology of Aging*, **2013**, 34, 1711.e7-13	5.6	36
164	Immunotherapy against amyloid pathology in Alzheimer's disease. *Journal of the Neurological Sciences*, **2013**, 333, 50-4	3.2	36
163	The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian case-control cohorts. *Alzheimerjs and Dementia*, **2013**, 9, 392-9	1.2	36
162	Epigenetic modulation of BDNF gene in patients with major depressive disorder. *Biological Psychiatry*, **2013**, 73, e6-7	7.9	66
161	Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 1938-42	5	81
160	An emerging role for long non-coding RNA dysregulation in neurological disorders. *International Journal of Molecular Sciences*, **2013**, 14, 20427-42	6.3	47
159	Intra-arterial chemotherapy with melphalan for intraocular retinoblastoma. *British Journal of Ophthalmology*, **2013**, 97, 1219-21	5.5	19
158	A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD. *Antioxidants and Redox Signaling*, **2013**, 19, 1662-75	8.4	18
157	Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. *Molecular Psychiatry*, **2013**, 18, 461-70	15.1	77
156	Inflammation in dry eye associated with rheumatoid arthritis: cytokine and in vivo confocal microscopy study. *Innate Immunity*, **2013**, 19, 420-7	2.7	36
155	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 1802-9	5	99

154	GRN Thr272fs clinical heterogeneity: a case with atypical late onset presenting with a dementia with Lewy bodies phenotype. *Journal of Alzheimerjs Disease*, **2013**, 35, 669-74	4.3	13
153	Gender effects on plasma PGRN levels in patients with Alzheimer's disease: a preliminary study. *Journal of Alzheimerjs Disease*, **2013**, 35, 313-8	4.3	13
152	Disease-modifying drugs in Alzheimer's disease. *Drug Design, Development and Therapy*, **2013**, 7, 1471-8	4.4	47
151	The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. *Clinical and Developmental Immunology*, **2013**, 2013, 939786		22
150	Novel missense progranulin gene mutation associated with the semantic variant of primary progressive aphasia. *Journal of Alzheimerjs Disease*, **2013**, 36, 415-20	4.3	14
149	Novel evidence of phenotypical variability in the hexanucleotide repeat expansion in chromosome 9. *Journal of Alzheimerjs Disease*, **2013**, 35, 455-62	4.3	15
148	Estrogens need insulin-like growth factor I cooperation to exert their neuroprotective effects in post-menopausal women. *Journal of Endocrinological Investigation*, **2013**, 36, 97-103	5.2	
147	Identification of a new susceptibility variant for multiple sclerosis in OAS1 by population genetics analysis. *Human Genetics*, **2012**, 131, 87-97	6.3	17
146	Progress in Alzheimer's disease. *Journal of Neurology*, **2012**, 259, 201-11	5.5	71
145	Pin1 contribution to Alzheimer's disease: transcriptional and epigenetic mechanisms in patients with late-onset Alzheimer's disease. *Neurodegenerative Diseases*, **2012**, 10, 207-11	2.3	28
144	Frontotemporal lobar degeneration: current knowledge and future challenges. *Journal of Neurology*, **2012**, 259, 2278-86	5.5	31
143	Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. *Neuroscience Letters*, **2012**, 530, 155-60	3.3	11
142	Investigation of c9orf72 in 4 neurodegenerative disorders. *Archives of Neurology*, **2012**, 69, 1583-90		83
141	MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. *Neuroscience Letters*, **2012**, 508, 4-8	3.3	79
140	Genetics of frontotemporal lobar degeneration. *Frontiers in Neurology*, **2012**, 3, 52	4.1	28
139	Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. *Neuropsychopharmacology*, **2012**, 37, 1647-55	8.7	145
138	Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: psychiatric clinical presentations. *Journal of Alzheimerjs Disease*, **2012**, 31, 447-52	4.3	59
137	Progranulin gene variability and plasma levels in bipolar disorder and schizophrenia. *PLoS ONE*, **2012**, 7, e32164	3.7	27

136	Possible influence of a non-synonymous polymorphism located in the NGF precursor on susceptibility to late-onset Alzheimer's disease and mild cognitive impairment. *Journal of Alzheimerjs Disease*, **2012**, 29, 699-705	4.3	16
135	Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients. *Journal of Alzheimerjs Disease*, **2012**, 30, 745-9	4.3	31
134	Sciatic endometriosis presenting as periodic (catamenial) sciatic radiculopathy. *Journal of Neurology* , **2012**, 259, 1470-1	5.5	7
133	Progress in multiple sclerosis research in the last year. *Journal of Neurology*, **2012**, 259, 1497-501	5.5	1
132	Clinical phenotypes and genetic biomarkers of FTLD. *Journal of Neural Transmission*, **2012**, 119, 851-60	4.3	16
131	SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Neurology*, **2012**, 79, 1556-62	6.5	228
130	Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study. *Neurodegenerative Diseases*, **2012**, 9, 121-7	2.3	77
129	A 66-year-old patient with vanishing white matter disease due to the p.Ala87Val EIF2B3 mutation. *Neurology*, **2012**, 79, 2077-8	6.5	13
128	The impact of osteopontin gene variations on multiple sclerosis development and progression. *Clinical and Developmental Immunology*, **2012**, 2012, 212893		25
127	Does vascular burden contribute to the progression of mild cognitive impairment to dementia?. *Dementia and Geriatric Cognitive Disorders*, **2012**, 34, 235-43	2.6	34
126	MicroRNAs as active players in the pathogenesis of multiple sclerosis. *International Journal of Molecular Sciences*, **2012**, 13, 13227-39	6.3	43
125	A trans-specific polymorphism in ZC3HAV1 is maintained by long-standing balancing selection and may confer susceptibility to multiple sclerosis. *Molecular Biology and Evolution*, **2012**, 29, 1599-613	8.3	19
124	Genetics and expression analysis of the specificity protein 4 gene (SP4) in patients with Alzheimer's disease and frontotemporal lobar degeneration. *Journal of Alzheimerjs Disease*, **2012**, 31, 537-42	4.3	6
123	The progranulin (GRN) Cys157LysfsX97 mutation is associated with nonfluent variant of primary progressive aphasia clinical phenotype. *Journal of Alzheimerjs Disease*, **2012**, 28, 759-63	4.3	11
122	Clinical, neuropathological, and genetic characteristics of the novel IVS9+1delG GRN mutation in a patient with frontotemporal dementia. *Journal of Alzheimerjs Disease*, **2012**, 30, 83-90	4.3	7
121	Disease-modifying drugs in multiple sclerosis: new oral options. *Clinical Practice (London, England)*, **2012**, 9, 315-327	3	
120	A functional variant in ERAP1 predisposes to multiple sclerosis. *PLoS ONE*, **2012**, 7, e29931	3.7	41
119	Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. *PLoS ONE*, **2012**, 7, e39186	3.7	45

118	Heterosexual pedophilia in a frontotemporal dementia patient with a mutation in the progranulin gene. *Biological Psychiatry*, **2011**, 70, e43-4	7.9	29
117	DNA methylation in repetitive elements and Alzheimer disease. *Brain, Behavior, and Immunity*, **2011**, 25, 1078-83	16.6	157
116	GSK3β genetic variability in patients with Multiple Sclerosis. *Neuroscience Letters*, **2011**, 497, 46-8	3.3	17
115	Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. *Neuroscience Letters*, **2011**, 504, 9-12	3.3	138
114	Study of thyroid hormone receptor alpha gene polymorphisms on Alzheimer's disease. *Neurobiology of Aging*, **2011**, 32, 624-30	5.6	12
113	No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort. *Neurobiology of Aging*, **2011**, 32, 1157-8	5.6	14
112	Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration. *Neurobiology of Aging*, **2011**, 32, 555.e1-8	5.6	26
111	Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. *Neurobiology of Aging*, **2011**, 32, 756.e11-5	5.6	72
110	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. *Alzheimerjs and Dementia*, **2011**, 7, 386-395.e6	1.2	291
109	A novel study and meta-analysis of the genetic variation of the serotonin transporter promoter in the italian population do not support a large effect on Alzheimer's disease risk. *International Journal of Alzheimerjs Disease*, **2011**, 2011, 312341	3.7	4
108	Lack of Association between the GPR3 Gene and the Risk for Alzheimer's Disease. *International Journal of Alzheimerjs Disease*, **2011**, 2011, 576143	3.7	
107	Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer's disease: genetics and expression analysis. *Journal of Alzheimerjs Disease*, **2011**, 26, 787-93	4.3	20
106	From genotype to phenotype: two cases of genetic frontotemporal lobar degeneration with premorbid bipolar disorder. *Journal of Alzheimerjs Disease*, **2011**, 27, 791-7	4.3	59
105	Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred. *Journal of Alzheimerjs Disease*, **2011**, 24, 253-9	4.3	57
104	Cerebrospinal fluid biomarkers in Progranulin mutations carriers. *Journal of Alzheimerjs Disease*, **2011**, 27, 781-90	4.3	42
103	A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia. *Journal of Alzheimerjs Disease*, **2011**, 26, 19-26	4.3	27
102	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nature Genetics*, **2011**, 43, 429-35	36.3	1421
101	APOE and Alzheimer disease: a major gene with semi-dominant inheritance. *Molecular Psychiatry*, **2011**, 16, 903-7	15.1	391

100	Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer's disease: the VITA and Milano studies. *Journal of Psychiatric Research*, **2011**, 45, 1250-6	5.2	11
99	Disease-modifying treatments for Alzheimer's disease. *Therapeutic Advances in Neurological Disorders*, **2011**, 4, 203-16	6.6	91
98	Cell-dependent kinase inhibitor 2A and 2B genetic variability in patients with Alzheimer's disease. *Journal of Neurology*, **2011**, 258, 704-5	5.5	0
97	Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. *Journal of Neuroinflammation*, **2011**, 8, 65	10.1	60
96	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature*, **2011**, 476, 214-9	50.4	1948
95	An APOE haplotype associated with decreased ε4 expression increases the risk of late onset Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2011**, 24, 235-45	4.3	42
94	Role of hnRNP-A1 and miR-590-3p in neuronal death: genetics and expression analysis in patients with Alzheimer disease and frontotemporal lobar degeneration. *Rejuvenation Research*, **2011**, 14, 275-81	2.6	45
93	Association of HLA class I markers with multiple sclerosis in the Italian and UK population: evidence of two independent protective effects. *Journal of Medical Genetics*, **2011**, 48, 485-92	5.8	9
92	Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. *Multiple Sclerosis Journal*, **2011**, 17, 819-29	5	69
91	Association of the CBLB gene with multiple sclerosis: new evidence from a replication study in an Italian population. *Journal of Medical Genetics*, **2011**, 48, 210-1	5.8	8
90	HLA-class I markers and multiple sclerosis susceptibility in the Italian population. *Genes and Immunity*, **2010**, 11, 173-80	4.4	47
89	GRN variability contributes to sporadic frontotemporal lobar degeneration. *Journal of Alzheimerjs Disease*, **2010**, 19, 171-7	4.3	27
88	The H1 haplotype of the tau gene (MAPT) is associated with mild cognitive impairment. *Journal of Alzheimerjs Disease*, **2010**, 19, 909-14	4.3	19
87	Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. *PLoS ONE*, **2010**, 5, e9287	3.7	51
86	Treatment of Alzheimer's disease: symptomatic and disease-modifying approaches. *Current Aging Science*, **2010**, 3, 46-56	2.2	36
85	FUS/TLS genetic variability in sporadic frontotemporal lobar degeneration. *Journal of Alzheimerjs Disease*, **2010**, 19, 1317-22	4.3	2
84	Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. *Genes and Immunity*, **2010**, 11, 497-503	4.4	13
83	A study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease. *Neuroscience Letters*, **2010**, 468, 1-2	3.3	10

82	Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. *Neuroscience Letters*, **2010**, 469, 234-6	3.3	21
81	Is KIF24 a genetic risk factor for Frontotemporal Lobar Degeneration?. *Neuroscience Letters*, **2010**, 482, 240-4	3.3	8
80	Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline. *Journal of Alzheimerjs Disease*, **2010**, 19, 1143-8	4.3	66
79	The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. *Journal of Alzheimerjs Disease*, **2010**, 22, 247-55	4.3	48
78	Failure to replicate an association of rs5984894 SNP in the PCDH11X gene in a collection of 1,222 Alzheimer's disease affected patients. *Journal of Alzheimerjs Disease*, **2010**, 21, 385-8	4.3	7
77	Candidate gene analysis of semaphorins in patients with Alzheimer's disease. *Neurological Sciences*, **2010**, 31, 169-73	3.5	9
76	Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. *Brain Research*, **2010**, 1333, 64-71	3.7	15
75	The CST3 B haplotype is associated with frontotemporal lobar degeneration. *European Journal of Neurology*, **2010**, 17, 143-6	6	11
74	Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort. *European Journal of Neurology*, **2010**, 17, 740-5	6	9
73	Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. *Journal of Alzheimerjs Disease*, **2009**, 18, 603-12	4.3	49
72	The serotonin transporter promoter polymorphic region is not a risk factor for Alzheimer's disease related behavioral disturbances. *Journal of Alzheimerjs Disease*, **2009**, 18, 125-30	4.3	11
71	Absence of TARDBP gene mutations in an italian series of patients with frontotemporal lobar degeneration. *Dementia and Geriatric Cognitive Disorders*, **2009**, 28, 239-43	2.6	8
70	Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy. *European Neurology*, **2009**, 62, 120-3	2.1	14
69	Analysis of the genes coding for subunit 10 and 15 of cytochrome c oxidase in Alzheimer's disease. *Journal of Neural Transmission*, **2009**, 116, 1635-41	4.3	13
68	Candidate gene analysis of selectin cluster in patients with multiple sclerosis. *Journal of Neurology*, **2009**, 256, 832-3	5.5	7
67	CCL8/MCP-2 association analysis in patients with Alzheimer's disease and frontotemporal lobar degeneration. *Journal of Neurology*, **2009**, 256, 1379-81	5.5	5
66	Interleukin-6 plasma level increases with age in an Italian elderly population ("The Treviso Longeva"-Trelong-study) with a sex-specific contribution of rs1800795 polymorphism. *Age*, **2009**, 31, 155-62		22
65	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nature Genetics*, **2009**, 41, 1094-9	36.3	1819

64	The NOS3 G894T (Glu298Asp) polymorphism is a risk factor for frontotemporal lobar degeneration. *European Journal of Neurology*, **2009**, 16, 37-42	6	20
63	DCUN1D1 is a risk factor for frontotemporal lobar degeneration. *European Journal of Neurology*, **2009**, 16, 870-3	6	12
62	Menopausal transition: a possible risk factor for brain pathologic events. *Neurobiology of Aging*, **2009**, 30, 71-80	5.6	27
61	Inclusion body myopathy and frontotemporal dementia caused by a novel VCP mutation. *Neurobiology of Aging*, **2009**, 30, 752-8	5.6	55
60	Is the ornithine transcarbamylase gene a genetic determinant of Alzheimer's disease?. *Neuroscience Letters*, **2009**, 449, 76-80	3.3	7
59	Alpha1-antichymotrypsin induces TNF-alpha production and NF-kappaB activation in the murine N9 microglial cell line. *Neuroscience Letters*, **2009**, 467, 40-2	3.3	10
58	Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. *Journal of the Neurological Sciences*, **2009**, 287, 291-3	3.2	72
57	Alzheimer's disease: from pathogenesis to novel therapeutic approaches. *Therapy: Open Access in Clinical Medicine*, **2009**, 6, 259-277		1
56	MCP-1 A-2518G polymorphism: effect on susceptibility for frontotemporal lobar degeneration and on cerebrospinal fluid MCP-1 levels. *Journal of Alzheimerjs Disease*, **2009**, 17, 125-33	4.3	17
55	Variations of the perforin gene in patients with multiple sclerosis. *Genes and Immunity*, **2008**, 9, 438-44	4.4	35
54	A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. *Genes and Immunity*, **2008**, 9, 7-15	4.4	19
53	The functional MAOA-uVNTR promoter polymorphism in patients with frontotemporal dementia. *European Journal of Neurology*, **2008**, 15, 637-9	6	5
52	Novel exon 1 progranulin gene variant in Alzheimer's disease. *European Journal of Neurology*, **2008**, 15, 1111-7	6	34
51	Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis. *Journal of the Neurological Sciences*, **2008**, 267, 86-90	3.2	26
50	Association of a NOS1 promoter repeat with Alzheimer's disease. *Neurobiology of Aging*, **2008**, 29, 1359-65	5.6	28
49	Interaction between the APOE epsilon4 allele and the APH-1b c + 651T > G SNP in Alzheimer's disease. *Neurobiology of Aging*, **2008**, 29, 1494-501	5.6	4
48	Role of VEGF gene variability in longevity: a lesson from the Italian population. *Neurobiology of Aging*, **2008**, 29, 1917-22	5.6	10
47	A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. *Cell*, **2008**, 133, 1149-61	56.2	263

46	Corneal involvement in rheumatoid arthritis: an in vivo confocal study. *Investigative Ophthalmology and Visual Science*, **2008**, 49, 560-4		110
45	MDC/CCL22 intrathecal levels in patients with multiple sclerosis. *Multiple Sclerosis Journal*, **2008**, 14, 547-9	5	21
44	Polymorphisms in the LOC387715/ARMS2 putative gene and the risk for Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2008**, 26, 169-74	2.6	6
43	Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. *Brain*, **2008**, 131, 3081-91	11.2	180
42	Preliminary evidence that VEGF genetic variability confers susceptibility to frontotemporal lobar degeneration. *Rejuvenation Research*, **2008**, 11, 773-80	2.6	22
41	Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 8050-4	11.5	74
40	Neuronal nitric oxide synthase C276T polymorphism increases the risk for frontotemporal lobar degeneration. *European Journal of Neurology*, **2008**, 15, 77-81	6	16
39	Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. *Neurogenetics*, **2008**, 9, 197-205	3	59
38	Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. *Journal of Neurology*, **2008**, 255, 539-44	5.5	64
37	Association study to evaluate the serotonin transporter and apolipoprotein E genes in frontotemporal lobar degeneration in Italy. *Journal of Human Genetics*, **2008**, 53, 1029-1033	4.3	8
36	CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. *European Journal of Neurology*, **2007**, 14, 162-7	6	19
35	IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease. *European Journal of Neurology*, **2007**, 14, e3-4	6	16
34	ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution. *Journal of Neuroimmunology*, **2007**, 186, 193-8	3.5	20
33	The cornea in Sjogren's syndrome: an in vivo confocal study. *Investigative Ophthalmology and Visual Science*, **2007**, 48, 2017-22		186
32	The leukocyte expression of CD36 is low in patients with Alzheimer's disease and mild cognitive impairment. *Neurobiology of Aging*, **2007**, 28, 515-8	5.6	19
31	Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. *Neurobiology of Aging*, **2007**, 28, 1682-8	5.6	16
30	Absence of TREM2 polymorphisms in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration. *Neuroscience Letters*, **2007**, 411, 133-7	3.3	18
29	Serum folate concentrations in patients with cortical and subcortical dementias. *Neuroscience Letters*, **2007**, 420, 213-6	3.3	7

28	Candidate gene analysis of SPARCL1 gene in patients with multiple sclerosis. *Neuroscience Letters*, **2007**, 425, 173-6	3.3	5
27	Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. *Neurology*, **2006**, 66, 146-7	6.5	53
26	Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. *Archives of Neurology*, **2006**, 63, 538-43		222
25	Progressive, isolated language disturbance: its significance in a 65-year-old-man. A case report with implications for treatment and review of literature. *Journal of the Neurological Sciences*, **2006**, 240, 45-51	2.2	13
24	SELPLG and SELP single-nucleotide polymorphisms in multiple sclerosis. *Neuroscience Letters*, **2006**, 394, 92-6	3.3	13
23	A novel polymorphism in SEL1L confers susceptibility to Alzheimer's disease. *Neuroscience Letters*, **2006**, 398, 53-8	3.3	22
22	Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. *Neuroscience Letters*, **2006**, 404, 217-21	3.3	15
21	Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. *Neurobiology of Aging*, **2006**, 27, 262-9	5.6	152
20	Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. *Neurobiology of Aging*, **2006**, 27, 770.e1-770.e5	5.6	40
19	Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. *Neurobiology of Aging*, **2006**, 27, 1763-8	5.6	153
18	Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. *Neurobiology of Aging*, **2006**, 27, 904-5	5.6	85
17	Genetics and neurobiology of frontotemporal lobar degeneration. *Neurological Sciences*, **2006**, 27 Suppl 1, S32-4	3.5	5
16	The T-786C NOS3 polymorphism in Alzheimer's disease: association and influence on gene expression. *Neuroscience Letters*, **2005**, 382, 300-3	3.3	25
15	P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with multiple sclerosis. *Neuroscience Letters*, **2005**, 388, 149-52	3.3	13
14	Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients. *Neurobiology of Aging*, **2005**, 26, 789-94	5.6	33
13	Non-progressive leukoencephalopathy with bilateral anterior temporal cysts: a case report and review of the literature. *Brain and Development*, **2005**, 27, 73-7	2.2	10
12	E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis. *Journal of Neuroimmunology*, **2005**, 165, 201-5	3.5	15
11	Vascular endothelial growth factor gene variability is associated with increased risk for AD. *Annals of Neurology*, **2005**, 57, 373-80	9.4	107

10	Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. *Muscle and Nerve*, **2005**, 32, 541-4	3.4	88
9	Association of neuronal nitric oxide synthase C276T polymorphism with Alzheimer's disease. *Journal of Neurology*, **2005**, 252, 985-6	5.5	15
8	Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments. *Expert Review of Neurotherapeutics*, **2004**, 4, 439-53	4.3	17
7	CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer's disease. *Journal of the Neurological Sciences*, **2004**, 225, 79-83	3.2	30
6	Inducible nitric oxide synthase (iNOS) in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. *Experimental Neurology*, **2004**, 187, 350-8	5.7	27
5	MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. *Neurobiology of Aging*, **2004**, 25, 1169-73	5.6	70
4	Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. *Annals of Neurology*, **2003**, 53, 547-8	9.4	101
3	Synergistic effect of beta-amyloid protein and interferon gamma on nitric oxide production by C2C12 muscle cells. *Brain*, **2000**, 123 (Pt 2), 374-9	11.2	21
2	The human astrocytoma cell line U373MG produces monocyte chemotactic protein (MCP)-1 upon stimulation with beta-amyloid protein. *Neuroscience Letters*, **2000**, 283, 177-80	3.3	43
1	Alpha-MSH peptides inhibit production of nitric oxide and tumor necrosis factor-alpha by microglial cells activated with beta-amyloid and interferon gamma. *Biochemical and Biophysical Research Communications*, **1999**, 263, 251-6	3.4	80